Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lung Neoplasms 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Pheochromocytoma 1Paraganglioma 1Papillary renal cell carcinoma, sporadic 1Pancreatic Ductal Adenocarcinoma 1Osteoradionecrosis 1Mouth Neoplasms 1Melanoma 1Hereditary leiomyomatosis and renal cell cancer 1Gliosarcoma 1Fallopian Tube Mucinous Adenocarcinoma 1Craniopharyngioma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Temozolomide 10Radiotherapy 5Radiation 4Magnetic Resonance Spectroscopy 4Ipilimumab 3pembrolizumab 2Specimen Handling 2Photons 2Nivolumab 2veliparib 1sargramostim 1peposertib 1montanide ISA 51 1liposomal doxorubicin 1cemiplimab 1balstilimab 1abexinostat 1X-Rays 1Vorinostat 1Utrogestan 1Surgical Procedures, Operative 1Sonication 1Progestins 1Progesterone 1Perfusion Magnetic Resonance Imaging 1Mycophenolic Acid 1Lomustine 1Irinotecan 1Drug Therapy 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × Contrast Media × 90 days × Clear all
NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡